Atlas Capital Advisors Inc. acquired a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) during the 4th quarter, Holdings Channel reports. The firm acquired 4,034 shares of the company’s stock, valued at approximately $708,000.
Several other institutional investors also recently modified their holdings of the company. L & S Advisors Inc bought a new stake in shares of AstraZeneca during the 4th quarter worth about $14,863,000. Monetary Management Group Inc. bought a new stake in shares of AstraZeneca during the 4th quarter worth about $1,097,000. Burling Wealth Partners LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth about $4,532,000. Hendley & Co. Inc. bought a new stake in shares of AstraZeneca during the 4th quarter worth about $11,373,000. Finally, Vaughan David Investments LLC IL bought a new stake in shares of AstraZeneca during the 4th quarter worth about $88,367,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Price Performance
Shares of AZNCF stock opened at $187.10 on Monday. The company has a 50-day simple moving average of $187.10 and a 200 day simple moving average of $186.00. AstraZeneca PLC has a 52 week low of $122.26 and a 52 week high of $195.00.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
See Also
- Five stocks we like better than AstraZeneca
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
